Live from ESMO 2023 | Oral Report Featuring Latest Data of Pelcitoclax (APG-1252) Combined with Osimertinib Demonstrates Potential as a New Treatment Option for TP53-and EGFR-Mutant NSCLC

SUZHOU, China and ROCKVILLE, Md., Oct. 23, 2023 /PRNewswire/ -- Ascentage Pharma , a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B , and...

Related Keywords

China ,Australia ,Beijing ,Rockville ,Western Australia ,Suzhou ,Jiangsu ,Madrid ,Spain ,Hong Kong ,Yifan Zhai ,Prnewswire Ascentage Pharma ,Ascentage Pharma ,Major National ,National Reimbursement Drug List ,Astrazeneca ,China National Medical Products Administration ,European Society Of Medical Oncology ,Dana Farber Cancer Institute ,Md Anderson Cancer Center ,Mini Oral ,Medical Oncology ,Chief Medical Officer ,Madrid Time ,Beijing Time ,Main Board ,Stock Exchange ,Hong Kong Limited ,Major National Rd Projects ,Major New Drug Projects ,New Drug Incubator ,Innovative Drug Programs ,Major Project ,Priority Review Designations ,Breakthrough Therapy Designations ,Drug Evaluation ,Reimbursement Drug List ,Orphan Drug Designation ,Fast Track Designation ,Orphan Designation ,Pediatric Disease ,Cancer Center ,Mayo Clinic ,Markets ,